In Brief: Aksys
This article was originally published in The Gray Sheet
Aksys: Investigational device exemption submission for the firm's PHD hemodialysis system is slated for submission in summer 1998, roughly nine months later than the firm previously had anticipated. In a June 6 release, the Lincolnshire, Illinois-based company says it will require additional time to "complete all performance specifications, validation and documentation requirements" for the device. Aksys maintains that the delay is "not a result of any technology or regulatory development," and does not reflect any "change in the feasibility of the product"...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.